reason report
reduc soliri revenu po earli gener ipr
bottom line follow last friday news us pto ptab
accept amgen ipr mp petit alexion soliri
patent revisit us soliri forecast updat model
account risk earlier acceler brand eros start
previous note publish last thursday afternoon
link simul downsid case ipr event assum
risk prevail us soliri biosimilar launch
alexion stock declin much friday reflect
high probabl earli launch certainli ptab
decis increas probabl event reflect
increas eros probabl success new alexion
model assum biosimilar soliri substitut
ultomiri us sinc dont exampl biosimilar
erod non-equival brand assum eros affect
indic soliri thu ad increment eros
per year longer term forecast soliri us forecast
alreadi assum signific eros acceler
result chang us soliri revenu forecast decreas
beyond chang reduc overal revenu forecast
compani
beyond base chang revenu forecast
associ multipl compress seem inevit
reduc target price
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target rate stock
outperform alexion lead compani develop commerci treatment
complement mediat diseas histor greater alexion revenu come
two rare diseas indic soliri recent approv soliri myasthenia
gravi upcom label expans on-going launch ultomiri alexion final
diversifi portfolio beyond soliri two core ahu pnh indic believ
alexion increas revenu complement franchis competit
threat soliri overst view given long safeti efficaci histori soliri
well alexion progress develop improv version ultomiri greater
potenc longer half-lif conveni dose beyond complement kanuma strensiq
continu grow steadili still believ two product could combin contribut
expect oper margin maintain futur
find alexion well posit grow ep doubl digit next five year
uspto data show ipr petit institut institut claim
accord uspto databas averag institut rate petit ipr
ptab past year institut petit find claim
origin patent invalid includ partial claim claim believ assumpt
probabl earli biosimilar launch larg consist uspto histor data
previous note ptab month reach final written decis
date institut put deadlin decis august howev ptab
final written decis either alexion depend result may request
rehear ptab appeal feder circuit like extend process
anoth month second half final decis thu believ mid-
timelin first possibl biosimilar launch remain reason
reduc us soliri forecast pt reduc
account risk earlier acceler brand eros reduc us soliri
forecast later year updat us soliri
forecast declin declin
later year gmg nmo indic approv ultomiri forecast
incorpor probabl biosimilar launch vs import note
chang affect soliri forecast us ultomiri thu less
effect overal revenu lower total alexion revenu forecast
later year ep estim reduc slightli given like
neg margin effect faster eros soliri adjust ep estim reduc
near term base lower revenu earn lower cash flow
like multipl compress next month reduc price target alexion
continu recommend stock although sentiment like consist
neg balanc potenti well well
price target base simpl averag three
approach believ reason basi valu stock today approach
simpl price earn multipl compar large-cap biopharma compani
ratio discount cash flow dcf use rel multipl similar growth
compani ep appli ep estim alexion give fair
valu stock use expect ep compound-annual-growth-rate alexion
period current averag ratio larg molecul large-cap biotech
give ep multipl discount multipl compress
alexion appli ep estim give fair valu final dcf
use termin growth rate post give current valu averag
three valuat methodolog pt
risk view outlook valuat alexion includ major chang price
reimburs coverag label soliri compani main product today risk
includ commerci develop disappoint recent launch product strensiq
kanuma well develop disappoint addit indic soliri
successor complement inhibitor product final brand gener competitor
product soliri come market captur greater share caus greater market price
disrupt current expect futur outlook valuat would undermin
opportun better perform valu expect includ stronger initi
adopt recent launch new product forecast success develop
commerci new indic soliri beyond neuromyel optica
myasthenia gravi novel rare diseas medicin time horizon forecast
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
brand
type event
event trial detail
date known
up/down
expect
european hear com patent
combin waiha pv ph data
later
combin waiha pv ph data
later
biomark endpoint prelud larger pivot
sound like patient clinic poc studi
initi phase
bridg trial pnh indic
phase studi investig
add-on current standard-of-car therapi
svb leerink llc research compani file
analysi stock price svb leerink target alexion
multipl ep svb leerink estimate earn
current averag larg cap biopharma multipl ep
svb leerink adjust ep estim
capit
number period
impli target price
method leerink intrins valu base dcf current product net
current svb leerink dcf marketed/l stage program
current estim valu asset
method project forward earn multipl ep base ep
compound-annual-growth-rate larg cap biotech ratio
averag growth larg cap biotech co
impli ep multipl discount vs full growth-adj multipl
averag method
svb leerink llc research compani file factset
svb leerink compani file zack factset consensu
svb leerink compani file zack factset consensu
